Table 6 Correspondence between in vitro activity and clinical efficacy in individual tumors
| Â | In vitro results | Clinical results |
|---|---|---|
Primary | Carboplatin/taxol | |
| Â | S/S | S |
| Â | R/S | S |
| Â | R/R | R |
| Â | R/R | R |
| Â | R/R | R |
| Â | R/R | R |
| Â | Carboplatin | |
| Â | R | R |
Recurrent | Carboplatin/taxol | |
| Â | S/S | S |
| Â | R/S | R |
| Â | S/S | S |
| Â | S/R | R |
| Â | R/R | R |
| Â | R/R | R |
| Â | R/R | R |
| Â | R/R | R |
| Â | R/R | R |
| Â | R/R | R |
| Â | R/R | R |
| Â | Cisplatin/adriamycin | |
| Â | R/R | R |
| Â | S/S | S |
| Â | S/S | S |
| Â | S/S | S |
| Â | R/R | R |
| Â | R/R | R |
| Â | Carboplatin | |
| Â | R | R |
| Â | R | R |
| Â | Carboplatin/gemcitabine | |
| Â | R/R | R |
| Â | R/R | R |
| Â | Carboplatin/taxol/gemcitabine | |
| Â | R/R/R | R |
| Â | R/R/R | R |